TABLE 1.
Patient demographics clinical characteristics adjusted for CYP3A5*3*6*7 metabolic composite groups.
|
CYP3A5*3*6*7 Metabolic Groups |
||||||
| Poor | Intermediate | Extensive | Overall | JT Trend P-value | ||
| N (%) | 35 (53.8) | 23 (35.4) | 7 (10.8) | 65 (100%) | ||
| Age (yrs) | Mean/Std/N | 49.8/12.6/35 | 48.5/11.0/23 | 45.4/9.0/7 | 48.9/11.6/65 | 0.426 |
| Gender | Male | 16 (45.7%) | 9 (39.1%) | 4 (57.1%) | 29 (44.6%) | |
| Female | 19 (54.3%) | 14 (60.9%) | 3 (42.9%) | 36 (55.4%) | 0.690 | |
| Race | Black | 6 (17.1%) | 20 (87.0%) | 7 (100.0%) | 33 (50.8%) | |
| White | 29 (82.9%) | 3 (13.0%) | 32 (49.2%) | <0.001 | ||
| Time Post-Transplant (yrs) | Mean/Std/N | 2.9/3.0/35 | 3.4/2.0/23 | 2.5/1.9/7 | 3.0/2.6/65 | |
| P-value | ||||||
| Serum Creatinine (mg/dl) | 1.3 (0.3) | 1.6 (0.40 | 1.7 (0.4) | 1.4 (0.4) | 0.001 | |
| Estimated Glomerular Filtration Rate ADJ Black Female (ml/min/1.73 m2) | 58.4 (14.3) | 54.0 (17.4) | 48.4 (13.1) | 55.8 (15.5) | 0.237 | |
| Glucose (mg/dl) | 114.7 (68.8) | 122.8 (79.3) | 93.0 (20.8) | 115.3 (69.2) | 0.449 | |
| Total White Blood Cells (x103 cells/mm3) | 5.4 (2.1) | 4.9 (1.7) | 5.9 (1.9) | 5.3 (1.9) | 0.361 | |
| Platelets (cells x 106) | 196.4 (46.5) | 195.6 (60.6) | 213.0 (45.4) | 197.9 (51.3) | 0.472 | |
| Hemoglobin (g/dl) | 12.4 (1.4) | 12.2 (1.4) | 12.2 (1.2) | 12.3 (1.4) | 0.870 | |
| Body Mass Index (kg/m2) | 29.8 (5.5) | 30.1 (6.9) | 31.6 (6.6) | 30.1 (6.1) | 0.758 | |
| Albumin (g/dl) | 4.1 (0.3) | 4.1 (0.30 | 4.1 (0.3) | 4.1 (0.3) | 0.874 | |
| Prednisone N(%) | 5 (14.3%) | 6 (26.1%) | 2 (28.6%) | 13 (20.0%) | 0.457 | |
| MPA trough at 12 h (mcg/dl) | 3.2 (1.7) | 4.1 (2.2) | 4.2 (2.9) | 3.7 (2.0) | 0.305 | |
P-values from two-sided Jonckheere–Terpstra Trend (JT) test.